Corporate Updates

Roche to Develop Companion Diagnostic Test for Dalcetrapi

Roche-62iqho39os8l6knqb75cb1et7b6isqcb4a3v2nhwusaRoche, a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, has signed an agreement to develop a companion diagnostic (CDx) test for dalcetrapib, a therapeutic from DalCor Pharmaceuticals (DalCor).The CDx test being developed by Roche will be used in a phase III clinical trial, which will validate the clinical efficacy of dalcetrapib.


DalCor is initially focused on providing precision medicine to patients through identification of patient populations that derive clinical benefits. By integrating clinical and genetic insights, DalCor and its partners intend to deliver superior outcomes in clinical medicine.

“At Roche, we understand the importance of forging partnerships that make significant impacts on patient lives,” said Paul Brown, Head of Roche Molecular Diagnostics. “Our first companion diagnostic test in cardiovascular disease represents a significant innovation, and leverages our expertise in developing FDA approved CDx tests. Working with DalCor is a good opportunity for us to enter this market and deliver on our mission of personalized healthcare.”

“The possibility of reducing morbidity and mortality for patients who have experienced ACS by identifying genetic markers that can respond to therapy, is an exciting prospect and one that we are eager to be a part of,” said Robert McNeil, CEO, DalCor Pharmaceuticals. “The DalCor and Roche collaboration for the genetic testing is the right combination for successful ution of the phase III trial.”


In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top